Skip to main content
Premium Trial:

Request an Annual Quote

GenMark to Offer $60M of Stock in Public Offering

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Monday that it plans to begin a public offering of $60 million of its common stock.

The company has not yet priced the offering.

Net proceeds will go toward general corporate purposes, such as acceleration of its test menu; furthering the development of its NexGen platform, expected to launch in the second half of 2014; the expansion of its domestic commercial team and acceleration of its international expansion; building up its administration infrastructure; automation of its manufacturing infrastructure; and other working capital requirements.

JP Morgan is the sole book-running manager for the proposed offering. GenMark said it intends to grant the underwriters a 30-day option to purchase up to $9 million in additional shares.

The Carlsbad, Calif.-based molecular diagnostics company last week reported a 44 percent increase in revenues for its second quarter.

In March, it filed a shelf registration to offer from time to time up to $150 million of its stock and/or other securities. In June 2012, GenMark raised about $39.3 million in a public offering of its stock.

In Thursday morning trade on the Nasdaq, shares of GenMark were down 3 percent at $9.43.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.